# Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery

> **NCT01612351** · PHASE2 · COMPLETED · sponsor: **UNC Lineberger Comprehensive Cancer Center** · enrollment: 40 (actual)

## Conditions studied

- Head and Neck Cancer
- Squamous Cell Carcinoma of the Head and Neck

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **DRUG:** Lapatinib
- **DRUG:** Cisplatin
- **DRUG:** Cisplatin
- **RADIATION:** Ipsilateral Radiation
- **RADIATION:** Bilateral Radiation
- **PROCEDURE:** Transoral Surgery

## Key facts

- **NCT ID:** NCT01612351
- **Lead sponsor:** UNC Lineberger Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2016-11
- **Final completion:** 2025-05-19
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2026-03-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01612351

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01612351, "Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01612351. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*